Clinical Trials
141
13 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1855
Active, not recruiting
9
6.4%
Completed
95
67.4%
Enrolling By Invitation
2
1.4%
Not yet recruiting
2
1.4%
Recruiting
25
17.7%
Terminated
7
5.0%
Withdrawn
1
0.7%
No approval data available
- The NIH has awarded a first installment of $4.6 million, part of up to $12.8 million over three years, to a multi-university team modeling drug-hormone interactions in women. - Thirteen researchers from Michigan State, Rutgers, Emory, Tulane, and other institutions will build computational models integrating age and reproductive cycle stage into drug predictions. - The project targets metabolic drugs such as metformin, insulin, and GLP-1 agents, whose effects may vary with shifting female hormone levels. - All computer models and data will be freely available worldwide, with findings intended to inform NIH guidelines and national safety standards.
- Researchers have for the first time identified and reconstructed the biosynthetic pathway for diterpenoid alkaloids from wolfsbane and larkspur, two highly toxic plants with known medicinal properties. - An international team from Michigan State University and the Czech Academy of Sciences transferred six key enzymes into tobacco plants, successfully producing the diterpenoid alkaloid atisinium. - The discovery provides a green, sustainable platform for producing these complex natural compounds at scale, potentially enabling new drugs for pain, malaria, and cancer. - The findings, published in Molecular Plant, solve a decades-old puzzle; aconitine, a related compound isolated nearly 200 years ago, has never been synthesized in a laboratory.
- MSU scientists identified the protein TPPP3 as a key driver of cisplatin resistance in ovarian cancer by stabilizing microtubules against chemotherapy-induced disruption. - Cancer cells with higher TPPP3 levels better withstand cisplatin or carboplatin, while patients with lower TPPP3 levels lived longer and responded better to treatment. - Removing TPPP3 in laboratory models significantly restored cancer cells' sensitivity to cisplatin, suggesting a new therapeutic strategy to overcome resistance. - Researchers are now developing drugs targeting TPPP3 and exploring its use as a biomarker to identify patients at risk of developing chemotherapy resistance.
- Eflornithine (DFMO), a decades-old drug originally used for West African sleeping sickness, has shown promising results in treating Bachmann-Bupp syndrome (BABS), an ultra-rare genetic disorder affecting only about 20 patients worldwide. - Five BABS patients treated with DFMO through FDA single-patient protocols have demonstrated visible improvements in muscle tone, developmental milestones, and hair growth by targeting the overactive ODC1 enzyme pathway. - A new collaboration between Corewell Health, Michigan State University, and Every Cure aims to accelerate research and navigate regulatory pathways to bring this potential treatment to more patients with the rare genetic condition. - The drug's established safety profile from previous uses provides researchers with dosing guidance and known side effects, offering advantages over developing entirely new medications for this orphan disease.
- TransCode Therapeutics published preclinical research in Molecular Imaging and Biology demonstrating a novel template-directed RIG-I agonist approach that selectively activates innate immune signaling within cancer cells. - The innovative strategy uses overexpressed oncogenic microRNAs like miRNA-21 as intracellular assembly templates to drive tumor-specific RIG-I activation while minimizing systemic toxicity. - The approach addresses longstanding challenges with RIG-I agonists including off-target immune activation and inefficient systemic delivery, while enabling non-invasive imaging of drug delivery. - The findings support the translational potential of TransCode's TTX nanoparticle delivery platform, which is currently being evaluated in clinical trials.
- PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18. - The newer agent flotufolastat F 18 offers unique advantages in postprostatectomy recurrence scenarios due to its reduced bladder activity, allowing better visualization of potential recurrence in the prostate bed. - While PSMA PET has largely replaced fluciclovine F 18, the metabolic tracer still maintains a role in specific scenarios including tumors with low PSMA expression and neuroendocrine differentiation cases. - Expert panels emphasize that agent selection often depends on institutional availability and specific clinical contexts, as detection rates and sensitivity remain comparable between different PSMA PET tracers.
• A 26-year-old bone cancer survivor has received the first known transplant of sperm-producing stem cells preserved from his childhood, marking a significant advancement in fertility preservation for pediatric cancer patients. • Approximately one-third of childhood cancer survivors face infertility from treatments, with prepubertal patients having limited options as they cannot bank mature reproductive cells before therapy. • The experimental procedure, developed at the University of Pittsburgh Medical Center, follows successful animal studies and represents a potential breakthrough in oncofertility, though researchers caution results remain uncertain.
